Korea / Special Situations, Clepsydra Capital

Sanghyun Park

Korea / Special Situations

Equity Capital Markets

Samsung Biologics   / Equity Capital Markets

Samsung BioLogics will have a big day tomorrow. Nov 2-3 will be the subscription day. The company has already had a huge success with the institutional investors during the demand survey. Hence, the company is widely expected to have a mega success in the next two days. Actually, the company's highly inflated valuation issue seems to be no longer relevant. Many investors (both domestic and overseas) seem to be betting on some intangible values, such as what "Samsung Brand" can do in the bio CMO industry and also BioLogics' unique position in Samsung restructuring process.

Samsung BioLogics will have a big day tomorrow. Nov 2-3 will be the subscription day. The company has already had a huge success with the institutional investors during the demand survey. Hence, the company is widely expected to have a mega success in the next two days. Actually, the company's highly inflated valuation issue seems to be no longer relevant. Many investors (both domestic and overseas) seem to be betting on some intangible values, such as what "Samsung Brand" can do in the bio CMO industry and also BioLogics' unique position in Samsung restructuring process.

Samsung BioLogics IPO - Why Investors Are Excited & Concerned

Samsung BioLogics is quite busy with NDR this week. BioLogics executives are doing their best to justify the proposed valuation for BioLogics IPO. It is not hard to figure out that the proposed valuation is quite inflated given that the company has never made any profit since its inception. Basically, BioLogics is arguing that its bio CMO (contract manufacturing organization) is worth ₩7.1tril and its 50% stake in Bioepis is worth ₩3.5tril. To come up with these valuations, BioLogics has used…

Samsung BioLogics is quite busy with NDR this week. BioLogics executives are doing their best to justify the proposed valuation for BioLogics IPO. It is not hard to figure out that the proposed valuation is quite inflated given that the company has never made any profit since its inception. Basically, BioLogics is arguing that its bio CMO (contract manufacturing organization) is worth ₩7.1tril and its 50% stake in Bioepis is worth ₩3.5tril. To come up with these valuations, BioLogics has used…

3 Main Debatable Points to Be Discussed in Samsung BioLogics NDR This Week

Samsung BioLogics has just filed an IPO report. I will summarize Samsung BioLogics IPO report in the following three parts:Part 1 - IPO ProceedingPart 2 - FinancialsPart 3 - ValuationBelow is Part 3 - Valuation.

Samsung BioLogics has just filed an IPO report. I will summarize Samsung BioLogics IPO report in the following three parts:Part 1 - IPO ProceedingPart 2 - FinancialsPart 3 - ValuationBelow is Part 3 - Valuation. 

Samsung BioLogics, Samsung Group's contract manufacturing organization (CMO) of bio logic drugs, is expected to seek preliminary approval from Korea Exchange on Thursday this week in an effort to go public on the main KOSPI market.It is currently the world's third-largest producer of biomedicines. Its annual production capacity is 180,000 liters, only behind Lonza (240,000 liters) and Boehringer Ingelheim (210,000 liters). Samsung BioLogics plans to use IPO money for expanding its annual…

Samsung BioLogics, Samsung Group's contract manufacturing organization (CMO) of bio logic drugs, is expected to seek preliminary approval from Korea Exchange on Thursday this week in an effort to go public on the main KOSPI market.It is currently the world's third-largest producer of biomedicines. Its annual production capacity is 180,000 liters, only behind Lonza (240,000 liters) and Boehringer Ingelheim (210,000 liters). Samsung BioLogics plans to use IPO money for expanding its annual…

Leading Independent Investment Research, Morningstar, Inc.

Morningstar

Leading Independent Investment Research

Morningstar, Inc.

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. We offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors. 

Morningstar provides data on more than 500,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 16 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries, with more than $180 billion in assets under advisement or management as of June 30, 2015. We have operations in 27 countries.

Download the Morningstar Fact Sheet : http://corporate.morningstar.com/US/documents/MarketingFactSheets/AboutMorningstarFactsheet.pdf

Thematic (Sector/Industry)

Democratic presidential candidates' potential drug policy reforms have pressured drug stocks, and ongoing political campaigns are likely to continue to create volatility despite the Republican-majority Congress and low probability of reforms passing into law.Among all the reforms, dual-eligible legislation—offering mandatory Medicaid-level drug rebates to some Medicare Part D beneficiaries— looks the most likely, and most impactful (5% earnings cut on average).Analysts: Karen Andersen, Damien Conover &amp; Kelsey Tsai

Democratic presidential candidates' potential drug policy reforms have pressured drug stocks, and ongoing political campaigns are likely to continue to create volatility despite the Republican-majority Congress and low probability of reforms passing into law.Among all the reforms, dual-eligible legislation—offering mandatory Medicaid-level drug rebates to some Medicare Part D beneficiaries— looks the most likely, and most impactful (5% earnings cut on average).Analysts: Karen Andersen, Damien Conover &amp; Kelsey Tsai

Low Odds of U.S. Drug Pricing Reforms Create Favorable Valuations

Switzerland

Lonza is a global partner to the pharmaceutical, biotech and nutrition markets. The company works with healthcare customers to develop, manufacture and commercialize medical treatments and technologies to treat patients against a range of diseases. Founded in the Swiss Alps, Lonza now operates across Europe, North America, South America, Asia and Oceania.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Lonza Group (LONN SE)

Samsung BioLogics IPO - Why Investors Are Excited & Concerned

Samsung BioLogics will have a big day tomorrow. Nov 2-3 will be the subscription day. The company has already had a huge success with the...

Sanghyun Park

3 Main Debatable Points to Be Discussed in Samsung BioLogics NDR This Week

Samsung BioLogics is quite busy with NDR this week. BioLogics executives are doing their best to justify the proposed valuation for BioLogics IPO....

Sanghyun Park

Samsung BioLogics IPO Part 3 - Valuation

Samsung BioLogics has just filed an IPO report. I will summarize Samsung BioLogics IPO report in the following three parts:Part 1 - IPO...

Sanghyun Park

Samsung BioLogics IPO Valuation Debate

Samsung BioLogics, Samsung Group's contract manufacturing organization (CMO) of bio logic drugs, is expected to seek preliminary approval from...

Sanghyun Park

Low Odds of U.S. Drug Pricing Reforms Create Favorable Valuations

Democratic presidential candidates' potential drug policy reforms have pressured drug stocks, and ongoing political campaigns are likely to...

Morningstar, Inc.

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)